65,437 trials
Infertility
Primary: Total Number of Oocytes — 12.4; 12.1 Number of oocytes
Metastatic Breast Cancer
Primary: Clinical Benefit Rate — 72.5; 67.0 Percentage of Participants — p=0.386
Constipation
Primary: Number of Participants With a Complete Resolution at the Final Visit — 36; 23 Participants — p=0.0595
Iron Overload
Primary: Occurrence of Adverse Events — 212 Adverse Events
Acromegaly
Primary: Serious Adverse Events (SAE) and Adverse Events (AE) — 116; 197 participants
Gastroesophageal Reflux Disease
Primary: Mean Change From Baseline to Month 12 for Hemoglobin Values — -0.29; -0.05 g/dL — p=0.042
Respiratory Insufficiency · Respiratory Failure
Primary: Breathing Comfort — 10; 40; 33.3; 45 visual analog scale
Bronchial Asthma
Primary: Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods — 14.3; 17.1 Liters/minute — p=0.6383
Antiplatelet Aggregation
Primary: Adjusted Mean Percent Changes From Baseline in Soluble CD40 Ligand (sCD40L) — 223.76; 35.04; 38.88; 32.74 percent change
Asthma
Primary: Improvement in FEV1 (Forced Expiratory Volume in 1 Second) Over the First 60 Minutes After Administration — 0.08; 0.07 Liters — p=0.775
Purpura, Thrombocytopaenic, Idiopathic
Primary: Number of Participants Who Responded (Platelet Count >=50 Gi/L and >=2x Baseline) to Eltrombopag Treatment in Cycle 2 or Cycle 3 Given Participants Responded in Cycle 1…
Hepatitis C, Chronic
Primary: The Number of Participants Who Achieve a Sustained Virologic Response (SVR) — 153; 144; 129 participants — p=0.041
HIV Infections · Peripheral Neuropathy
Primary: Change From Baseline for Numerical Rating Scale (NRS) Pain Scores at Endpoint-LOCF (Last Observation Carried Forward) Relative to Baseline — -2.88; -2.63 score on scale…
Cancer · Refractory Solid Tumor
Primary: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RPIID) of Cetuximab in Combination With Irinotecan — 250; 250; 16; 20 mg/m2
Rhinitis
Primary: Adverse Events — 3; 1 Participants